Study of Ipatasertib (GDC-0068)
Study of Ipatasertib (GDC-0068)
Type/Disease Site:
Breast
Trial Category:
Breast
Phase
III
Contact(s)
A Phase II Randomized, Double-blind, Study of Ipatasertib (GDC-0068), An AKT inhibitor, In combination with Paclitaxel as neoadjuvant treatment for patients with early stage triple negative breast cancer
